Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
24. Oktober 2022 07:30 ET
|
Beyond Air™
-- Duration of oxygen support was significantly shorter for subjects treated with inhaled NO LungFit PRO safely delivered 150 ppm NO in the hospital-- GARDEN CITY, N.Y., Oct. 24, 2022 (GLOBE...
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast
20. Oktober 2022 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment...
Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022
17. Oktober 2022 16:05 ET
|
Beyond Air™
-- Data show favorable safety, tolerability, and efficacy results -- -- All patients titrated to 250 ppm NO with no patients needing to reduce concentration -- -- All patients demonstrated ability...
Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting
05. Oktober 2022 08:00 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration...
Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis
03. Oktober 2022 07:30 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment...
Beyond Air® To Participate in Three Upcoming Investor Conferences
16. September 2022 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the...
Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)
23. August 2022 08:00 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration...
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023
11. August 2022 16:05 ET
|
Beyond Air™
Initiated U.S. commercial launch of LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Will present data from...
Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast
27. Juli 2022 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., July 27, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment...
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022
28. Juni 2022 16:10 ET
|
Beyond Air™
LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented...